News

Albireo has completed the Phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the data revealed appropriate

Teva UK has entered the G-CSF therapy area, by developing biosimilar medicines. The company has launched its proprietary version of filgrastim,’TevaGrastim’. TevaGrastim is licensed for a number of

Basilea’s Toctino (alitretinoin), a once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to topical corticosteroids, has obtained regulatory approval from Health Canada. Toctino has

The expanded facility has been fully validated, and will continue to deliver the same high-quality Sensititre products, including the Sensititre microbroth dilution plates used in clinical and veterinary

ARYx Therapeutics has announced the review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx’s compound for the treatment of

India-based Kunnath Pharmaceuticals is seeking new license to manufacture its Musli Power Xtra with a formula including Safed Musli. The company has approached Ayurvedic Drug Control office in

Bafna Pharmaceuticals has received approval from Sri Lankan authorities for the launch of Olmesartan Medoxomil, anti-hypertension drug. The drug will be launched as Olmebaf, and will initiate marketing

Millennium has expanded its protein homeostasis program with the initiation of Phase I clinical trial for an oral formulation of MLN9708, a proteasome inhibitor. An intravenous formulation of

Pfizer has reported that FDA’s Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent